Document Detail


Antipsychotic drugs and relapse prevention.
MedLine Citation:
PMID:  10190229     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Strategies for preventing relapse during the maintenance or stable phase of schizophrenia are discussed for both conventional and newer antipsychotics. For conventional agents, strategies focus on finding dosages that minimize antipsychotic drug side effects and provide adequate protection against psychotic relapse. Although few studies are available to compare older and newer antipsychotics for preventing relapse, there are reasons for proposing that newer drugs will be shown to be superior. Because of their milder side effects, clinicians can choose drug dosages that provide maximum protection against relapse. Further, since patients on the newer drugs are likely to experience fewer discomforting side effects, they may be more likely to take their medications as directed. Other potential advantages of the newer drugs over the older drugs include the likelihood that they are more effective against negative and cognitive symptoms of schizophrenia.
Authors:
S R Marder
Related Documents :
12143799 - Therapeutic drug monitoring: chemical-clinical correlations of atypical antipsychotic d...
6996079 - Biochemical processes in schizophrenia: an update.
16051409 - Patterns of clinical use of antipsychotics in hospitalized psychiatric patients.
7901179 - Self-reported prescribing practices for schizophrenic patients among israeli psychiatri...
7387339 - Propranolol in schizophrenia. clinical, metabolic, and pharmacological findings.
9408199 - The common marmoset (callithrix jacchus) as a model for neuroleptic-induced acute dysto...
16214789 - Use of porous aluminosilicate pellets for drug delivery.
8391359 - An optimal time control problem for the administration of 2',3'-dideoxycytidine by usin...
10429839 - The low potential for drug interactions with zanamivir.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Schizophrenia research     Volume:  35 Suppl     ISSN:  0920-9964     ISO Abbreviation:  Schizophr. Res.     Publication Date:  1999 Mar 
Date Detail:
Created Date:  1999-07-21     Completed Date:  1999-07-21     Revised Date:  2010-09-02    
Medline Journal Info:
Nlm Unique ID:  8804207     Medline TA:  Schizophr Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  S87-92     Citation Subset:  IM    
Affiliation:
Psychiatry Service, West Los Angeles Veterans Affairs Medical Center, CA 90073, USA. marder@ucla.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antipsychotic Agents / therapeutic use*
Benzodiazepines
Clozapine / therapeutic use
Humans
Pirenzepine / analogs & derivatives,  therapeutic use
Recurrence / prevention & control
Risperidone / therapeutic use
Schizophrenia / drug therapy*
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 106266-06-2/Risperidone; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine; 28797-61-7/Pirenzepine; 5786-21-0/Clozapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neuroleptic-induced hyperprolactinemia.
Next Document:  Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.